Phase 3 N=169 Effect of D-cycloserine Plus Cognitive Behavioral Therapy on People With Social Phobia
Social Anxiety Disorder
Primary: Social Phobic Disorders Severity and Change Form — 2.68; 2.95 Units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=458 A Study of Duloxetine (LY248686) in Participants With Chronic Low Back Pain
Back Pain Lower Back Chronic
Primary: Change From Baseline to Week 14 in Brief Pain Inventory (BPI) 24-Hour Average Pain Severity Item — -2.43; -1.96 units on a scale — p=0.0026
Phase 3 N=360 A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma
Primary: Percentage of Participants Achieving CR or PR at the End of Therapy — 75.0; 92.4 percentage of participants — p=0.0009
Phase 3 N=89 Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis
Multiple Myeloma and Plasma Cell Neoplasm
Primary: Hematologic Response Rate — 55.9; 69.1 percentage of participants
Phase 3 N=162 A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal Therapy
Prostate Cancer
Primary: The Rate of Suppression of Serum Testosterone to Castrate Level — 81; 78; 0; 1 Participants
Phase 3 N=140 An Open-label Randomized Multicenter Phase III Clinical Study Comparing Safety and Efficacy of Algeron (Cepeginterferon Alfa-2b) and and PegIntron (Peginterferon Alfa-2b) in Combination With Ribavirin as Combined Treatment of Chronic Hepatitis C in Human Immunodeficiency Virus-1 Infected Patients
Hepatitis · Hepatitis C · Hepatitis C/ Human Immunodeficiency Virus Coinfection
Primary: Early Virological Response — 90.0; 81.4 percentage of patients — p=0.227
Phase 3 N=64 Once-daily Oral Modified Release Hydrocortisone in Patients With Adrenal Insufficiency
Adrenal Insufficiency
Primary: Area Under the Concentration Time Curve From Zero to 24 Hours (AUC0-24h) of Total S-cortisol in Plasma After Multiple Doses During Part A — 3962.0; 4879.6 hour*nanomole…
Phase 3 N=77 A Study of RoActemra/Actemra (Tocilizumab) With or Without Methotrexate in Patients With Mild to Moderate Rheumatoid Arthritis With an Inadequate Response to Methotrexate
Rheumatoid Arthritis
Primary: Change From Week 12 (Randomization) to Week 24 in DAS28 — 0.17; -0.16 score on a scale — p=0.188
Phase 3 N=2,624 Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)
Pulmonary Disease, Chronic Obstructive
Primary: Forced Expiratory Volume in One Second (FEV1) Area Under the Curve (AUC) (0-3h) Response on Day 169. — 0.133; 0.148; 0.139; 0.241 Litres — p=<0.0001
Phase 3 N=43 Efficacy Study of Adalimumab to Treat Interstitial Cystitis
Interstitial Cystitis
Primary: O'Leary-Santa Interstitial Cystitis Symptom Index and Problem Index (OSPI) Score — 27.7; 27.8; 19.6; 19.9 units on a scale — p=0.75
Phase 3 N=2,539 Tiotropium +Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)
Pulmonary Disease, Chronic Obstructive
Primary: Forced Expiratory Volume in One Second (FEV1) Area Under the Curve (AUC) (0-3h) Response on Day 169 — 0.136; 0.125; 0.165; 0.256 Litres — p=<0.0001
Phase 3 N=219 Characterization of 24-hour Lung Function Profiles of Inhaled Tiotropium + Olodaterol Fixed Dose Combination in Patients Suffering From Chronic Obstructive Pulmonary Disease
Pulmonary Disease, Chronic Obstructive
Primary: Forced Expiratory Volume in 1 Second (FEV1) AUC0-24h Response [L] After 6 Weeks Treatment. — -0.037; 0.129; 0.117; 0.133 Litres (L) — p=<0.0001
Phase 3 N=68 Bone Properties in Hypoparathyroidism: Effects of PTH
Hypoparathyroidism
Primary: Requirements for Calcium Supplementation — 3.03; 1.66 grams per day of calcium supplementation
Phase 3 N=1,001 A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Primary: Change From Baseline in Standardized Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC) (0-12 Hours (h)) — 0.234; 0.122; 0.155; -0.028 Liters
Phase 3 N=1,072 A Study in Second Line Metastatic Colorectal Cancer
Colorectal Cancer
Primary: Overall Survival (OS) — 13.3; 11.7 months — p=0.0219